Hypothalamic-Pituitary Autoimmunity and Related Impairment of Hormone Secretions in Chronic Fatigue Syndrome.
De Bellis, Annamaria, Bellastella, Giuseppe, Pernice, Vlenia et al. · The Journal of clinical endocrinology and metabolism · 2021 · DOI
Quick Summary
This study looked for specific immune system antibodies that attack the pituitary and hypothalamus—two small brain structures that control hormone production—in people with ME/CFS. Researchers found these antibodies in more than half of ME/CFS patients but none in healthy controls. Patients with these antibodies had lower levels of important hormones (like cortisol and growth hormone), and those with the highest antibody levels had the most severe ME/CFS symptoms.
Why It Matters
This study provides evidence that autoimmune mechanisms targeting hormone-regulating brain structures may contribute to ME/CFS symptoms and severity. If these findings are confirmed in larger, diverse populations, it could lead to new diagnostic tests and targeted treatments for ME/CFS patients, particularly those with more disabling forms of the illness.
Observed Findings
56% of ME/CFS patients had antipituitary antibodies compared to 0% of healthy controls
33% of ME/CFS patients had antihypothalamic antibodies compared to 0% of healthy controls
Patients with high-titer antibodies had significantly lower ACTH/cortisol levels than antibody-negative patients
Patients with high-titer antibodies had significantly lower growth hormone peaks and IGF-1 levels than antibody-negative patients
Patients with high-titer antibodies reported more severe ME/CFS symptoms than those with middle/low-titer or no antibodies
Inferred Conclusions
Hypothalamic-pituitary autoimmunity is prevalent in ME/CFS and may contribute to neuroendocrine dysfunction in this population
Autoantibody titer level correlates with both hormonal deficiency severity and ME/CFS disease severity
Autoimmune hypothalamic-pituitary dysfunction may represent a pathogenic mechanism underlying ME/CFS, particularly in more severe cases
Remaining Questions
Do these antibodies cause ME/CFS, or do they develop as a consequence of the disease?
Would these antibodies be useful as a biomarker to identify ME/CFS patients or predict disease severity?
What This Study Does Not Prove
This study does not prove that these antibodies cause ME/CFS—it shows they are associated with the disease but cannot establish causation from a case-control design. The small sample size (30 patients) and enrollment of only women limits whether these findings apply to all ME/CFS patients. It also does not establish whether identifying these antibodies would change patient treatment or outcomes.